News & EventsLearn more about ReForm Biologics and our commitment to innovation in biotherapeutics.
ReForm Biologics Announces Issuance of U.S. Patent for New Excipient to Improve Antibody-Based Therapeutics
ReForm Biologics to present at the 13th annual PEGS Summit
ReForm Biologics, a pharmaceutical technology company developing an innovative platform to improve biologic formulations, announced today the issuance of U.S. patent 9,605,051 (the ‘051 patent) for one of its new excipient formulations.
ReForm Biologics Appoints John M. Sorvillo, Ph.D., as Chief Executive Officer
Dr. Sorvillo brings over 25 years of experience leading the development and licensing of technologies, from discovery platforms and research programs to pre-clinical and clinical products, across a range of therapeutic areas.
PEGS Boston – May 1-5, 2017
ReForm Biologics will present new results in the poster session at the PEGS Summit at Boston Seaport World Trade Center May 3-4, 2017. View poster here or visit us at our poster – B92.
BIO 2017, San Diego – June 19-22, 2017
Please arrange a meeting through the partnering system at BIO 2017.
BioProcess International Conference & Exhibition – September 25-28, 2017
ReForm Biologics will present details of a new excipient study in the “Drug Product, Fill Finish & Formulations” track at the BioProcess International (BPI) conference, taking place September 25-28, 2017 at the Hynes Convention Center in Boston. Conference details are available at: https://lifesciences.knect365.